Troutman Pepper Locke advised Eupraxia Pharmaceuticals, Inc. (Eupraxia) (NASDAQ: EPRX; TSX: EPRX), a clinical-stage biotechnology company developing targeted therapies that leverage a proprietary extended-release delivery system to provide the right dose of a drug, in its public offering of 14,636,363 common shares at $5.50 per common share for gross proceeds of approximately $80.5 million, before deducting the underwriting commissions and estimated expenses incurred in connection with the offering. For more information, see the press release.
The Troutman Pepper Locke team that advised Eupraxia was led by Tom Rose, Shona Smith, Nicole Edmonds, Alex Yarbrough, Jason Langford, Taylor Williams, and Joe Cataldo, and included Mark Goldsmith, Noreen Onimus, Heather Morehouse Ettinger, and Judy O’Grady.